English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Regulatory
C.D. Marsden
| Apr 12, 2025
Empower Pharmacy: Eli Lilly lawsuit is ‘Big Pharma’s attempt to limit patient and provider choice’
+
Community
Patient Daily
| Apr 17, 2025
ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+
Pharmaceuticals
Patient Daily
| Apr 15, 2025
UCSF neurosurgeon: '340B is a drug discount program that hospitals exploit as an additional revenue stream'
+
Pharmaceuticals
Patient Daily
| Apr 17, 2025
AI tool decodes cerebellar signals to improve understanding of brain disorders
